ArticleNPJ precision oncology2025
Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.
Sara Arce-Gallego et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it